UCB announces initial clinical trial results involving patients taking certolizumab pegol for modera
(Thomson Reuters ONE) -
Unternehmensinformation / Kurzprofil:Bereitgestellt von Benutzer: hugin
Datum: 21.12.2009 - 07:00 Uhr
Sprache: Deutsch
News-ID 9879
Anzahl Zeichen: 0
contact information:
Town:
Kategorie:
Diese Pressemitteilung wurde bisher
514 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
UCB announces initial clinical trial results involving patients taking certolizumab pegol for modera"
steht unter der journalistisch-redaktionellen Verantwortung von
UCB (
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
- 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
- Data include an open-label extension study describing the long-term safety of FINTEPLA® ...
Brussels, Belgium, December 15 2009 - 8:30 (CET). Regulated
information. - UCB SA ("UCB" or the "Company") is pleased to announce
the signing of its new EUR 1.5 billion revolving credit facility.
The purpose of the facility is to ...
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER
JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY
APPLICABLE LAW
The current news release consti ...
